Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Healthcare Drug Manufacturers - Specialty & Generic
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > BMO gets it..
View:
Post by whitenorth72 on Dec 21, 2023 11:24am

BMO gets it..

Recent Trades - Last 10 of 13
Time ET Ex Price Change Volume Buyer Seller Markers
10:32:07 V 0.06 0.01 20,000 9 BMO Nesbitt 2 RBC K
10:32:07 V 0.06 0.01 5,000 9 BMO Nesbitt 85 Scotia K
10:32:07 V 0.06 0.01 12,000 9 BMO Nesbitt 85 Scotia K
10:32:07 V 0.06 0.01 8,000 9 BMO Nesbitt 19 Desjardins K
10:32:07 V 0.06 0.01 19,000 9 BMO Nesbitt 7 TD Sec K
10:20:02 V 0.06 0.01 80,000 2 RBC 2 RBC K
09:38:05 H 0.06 0.01 7,000 9 BMO Nesbitt 7 TD Sec K
09:38:05 H 0.06 0.01 1,000 9 BMO Nesbitt 1 Anonymous K
09:34:17 V 0.055 0.005 20,000 9 BMO Nesbitt 85 Scotia K
09:34:17 H 0.055 0.005 1,000 9 BMO Nesbitt 1 Anonymous K
Comment by postie1 on Dec 21, 2023 7:24pm
With all the news I am in BMOs corner. Put in a stink bid and do not really care if I get it because it is to my benefit if the stock rises but if someone does some stunt I will gladly take them. Right or wrong will be determined at a later date. Anybody that bought at .035 or .04  is looking good at this point( 5 thumbs up to those that had the nerve to pull a big trigger when the stock was ...more  
Comment by postie1 on Dec 22, 2023 2:15pm
Vm is trading over 200,000 so far today when you include alternate exchanges
Voyageur Pharmaceuticals Ltd
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


PRODUCTS PIPELINE CARBON DRUG PROJECT WHITE PAPER CASE STUDIES MANAGEMENT PRESENTATION

Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1